Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03044223

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinic of Anesthesiology

Ulm, 89070, Germany

Location status: Recruiting

Location contact

Andreas Essig, MD

SUB_INVESTIGATOR

Anne Sedlag, Biochemist

PRINCIPAL_INVESTIGATOR

Christian Riedel, PhD

SUB_INVESTIGATOR

Doris Henne-Bruns, MD

SUB_INVESTIGATOR

Eberhard Barth, MD

CONTACT

[email protected]

+49-(0)731-500-60050

Eberhard Barth, MD

SUB_INVESTIGATOR

Florian Gebhard, MD

SUB_INVESTIGATOR

Hendrik Bracht, MD

SUB_INVESTIGATOR

Karl-Heinz Orend, MD

SUB_INVESTIGATOR

Manfred Weiss, MD, MBA

CONTACT

[email protected]

+49-(0)731-500-60226

Marc-Eric Halatsch, MD

SUB_INVESTIGATOR

Michael Goergieff, MD

SUB_INVESTIGATOR

About this study

During bacterial related sepsis, one of the key playing cells are macrophages, monocytes and T-lymphocytes (Hotchkiss et al., 2003). Macrophages and monocytes are supposed to be essential for the septic reaction to Gram-negative bacteria (Hotchkiss et al. 2003). Generally, there are two dominant types of macrophages: the pro-inflammatory M1 macrophage and the anti-inflammatory M2 macrophage (Mantovani et al., 2006). Similar to this macrophage characteristics, monocytes can also be categorized into pro-or anti-inflammatory. These macrophage/monocyte phenotypes can be differentiated in vitro from freshly isolated human blood monocytes using either GM-CSF giving raise to M1 macrophage/monocyte or M-CSF resulting in M2 macrophage/monocyte (Mantovani et al., 2006; Neu et al., 2013). Brunialti et al. (2012) have already demonstrated that the population of antiinflammatory M2 monocytes in septic patients is bigger than the pro-inflammatory M1 population. However, the authors did not further analyze the underlying mechanisms of M2 polarization nor did they identify the sepsis-causing pathogens.

In the present study, monocytes and macrophages of patients with Pseudomonas aeruginosa (PSA) sepsis are characterized by their surface marker expression profile via flow cytometry and cytokine pattern by ELISA in vivo and after ex-vivo LPS stimulation. In addition, an ex-vivo model system for PSA induced sepsis is validated. Blood of critically ill patients in the ICU infected with PSA is sampled to isolate peripheral blood mononuclear cells (PBMCs). Blood monocytes are analyzed for surface marker expression to determine the relative proportions of M1 and M2 monocytes in these patients and in healthy controls by flow cytometry

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age > 18 years
  • critically ill patients with sepsis
  • microbiologically proven infection with Pseudomonas aeruginosa

Exclusion criteria

  • life expectancy < 24 hours
  • participation in other studies

Treatment and study plan

Primary outcomes

  1. Monocyte surface marker expression in critically ill patients with Pseudomonas aeruginosa sepsis

    Time frame: two years

    Monocyte type 1, type 2 surface marker expression

Secondary outcomes

  1. Cytokine concentrations in serum and production after ex-vivo stimulation of isolated monocytes of critically ill patients with Pseudomonas aeruginosa sepsis with LPS

    Time frame: four years

    IL-8 and IFN-gamma

Study contacts

Contact information is provided by the study sponsor or research team.

Eberhard Barth, MD

CONTACT

[email protected]

+49 731 500 60050

Manfred Weiss, MD, MBA

CONTACT

[email protected]

+49 731 500 60226

Sponsors and collaborators

Lead sponsor

University of Ulm

Other

Registry information

Official study title

Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis

Acronym: MIPSA

Important dates

Study start
2014
Primary completion
2025
Study completion
2026
First posted
Feb 6, 2017
Registry last updated
Jan 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.